Sionna Therapeutics, Inc.

SION

Held by 9 specialist biotech funds

High Convergence

9 funds opened new positions. Next phase2 readout (SION-719): Jul 2026. Short interest: 15.2% of float.

BiotechnologyCEO: Michael CloonanIPO: 2025Website ↗

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

Sionna Therapeutics, Inc.

Signal Score

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research